

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

Michael Böhm, Stefan Anker, Felix Mahfoud, Lucas Lauder, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Martina Brueckmann, Ilias Saloustros, Elke Schüler, et al.

▶ To cite this version:

Michael Böhm, Stefan Anker, Felix Mahfoud, Lucas Lauder, Gerasimos Filippatos, et al.. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. European Heart Journal, 2022, pp.396-407. 10.1093/eurheartj/ehac693. hal-03892037

HAL Id: hal-03892037 https://hal.univ-lorraine.fr/hal-03892037

Submitted on 9 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

Michael Böhm (1)¹*, Stefan Anker (1)^{2,3}, Felix Mahfoud (1)¹, Lucas Lauder (1)¹, Gerasimos Filippatos (1)⁴, João Pedro Ferreira (1)^{5,6}, Stuart J. Pocock (1)⁷, Martina Brueckmann (1)^{8,9}, Ilias Saloustros¹⁰, Elke Schüler¹¹, Christoph Wanner (1)¹², Faiez Zannad (1)^{5,6}, Milton Packer (1)^{13,14}, and Javed Butler^{13,15}, on behalf of the EMPEROR-Preserved Trial Committees and Investigators

¹Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Kirrberger Str. 1, 66421 Homburg, Saarland, Germany, ²Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies (BCRT), Augustenburger Platz 1, 13353 Berlin, Germany, ³Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany, ⁴National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, 1Rimini St, 12462 Athens, Greece; ⁵Université de Lorraine, Centre d'Investigation Clinique-Plurithématique Insern CIC-P 1433, 54500 Vandoeuvre-Les-Nancy, France; ⁶Insern U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 54500 Vandoeuvre-Les-Nancy, France; ⁷Department of Medicine, Athens Onivorsity Hospital Attikon, 1Rimini St, 12462 Athens, Greece; ⁵Université de Lorraine, Centre d'Investigation Clinique-Plurithématique Insern CIC-P 1433, 54500 Vandoeuvre-Les-Nancy, France; ⁶Insern U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 54500 Vandoeuvre-Les-Nancy, France; ⁷Department of Medicial Statistics, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK; ⁸Boehringer Ingelheim International, Binger Str. 173, 55218 Ingelheim, Rheinland-Pfalz, Germany; ⁹First Department of Medicine, Faculty of Medicine Rannheim, University of Heidelberg, Grabengasse 1, 69117 Heidelberg, Baden-Württemberg, Germany; ¹⁰Medical Department, Boehringer Ingelheim TA Cardiometabolism Respiratory Medicine, Ringstr. 173, 55218 Ingelheim, Germany; ¹¹Mainangtics MoHH, Sulzbach, Otto-Volger-Str. 3c, 65843 Sulzbach/Taunus, Hessen, Germany; ¹²Medizinische Klinik und Poliklinik 1, Schwerpunkt Nephrologie, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080 Würzburg, Bayern, Germany; ¹³Baylor Heart and Vascular Institute, Baylor University Medical Center, 3500 Gasto

Received 11 May 2022; revised 7 October 2022; accepted 10 November 2022

Abstract

Aims	Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic blood pressure (SBP) moderates these effects.
Methods and results	The association of SBP and the treatment effects of empagliflozin in EMPEROR-Preserved (empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction) was evaluated. Randomized patients ($n = 5988$) were grouped according to SBP at baseline (<110 mmHg, $n = 455$; 110–130 mmHg, $n = 2415$; > 130 mmHg, $n = 3118$). The effect of empagliflozin on blood pressure, cardiovascular death or HF hospitalization (primary outcome), total HF hospitalizations, and rate of decline in estimated glomerular filtration rate was studied. Over a median of 26.2 months, the placebo-corrected decline was small and not significantly different across baseline SBP. On placebo, the risk of cardiovascular death or hospitalization for HF was 8.58 at >130 mmHg, 8.26 at 110–130 mmHg, and 11.59 events per 100 patient-years at <110 mmHg ($P = 0.12$ vs. > 130 mmHg, $P = 0.08$ vs. 110–130 mmHg). There was no evidence for baseline SBP moderating the effect of empagliflozin on risk of HF events (primary endpoint interaction $P = 0.69$, recurrent HF hospitalizations interaction $P = 0.55$). When comparing empagliflozin with placebo, SBP did not meaningfully associate with adverse events such as hypotension, volume depletion, and acute renal failure.
Conclusion	In EMPEROR-Preserved, empagliflozin was effective and safe without SBP meaningfully moderating empagliflozin's treat- ment effects. This analysis of EMPEROR-Preserved shows that empagliflozin can be used safely and effectively without blood pressure being a meaningful moderator of the drug benefit.
Clinical Trial Registration	URL: https://www.clinicaltrials.gov Unique identifier: NCT03057951

* Corresponding author. Tel: (+49) 6841 16 15031, Fax: (+49) 6841 16 15032, Email: michael.boehm@uks.eu

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Structured Graphical Abstract

Key Question


Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. The interaction of this beneficial effect with baseline blood pressure remains unknown.

Key Finding

In the EMPEROR-preserved trial the placebo corrected changes of systolic blood pressure were small and not significantly different across baseline systolic blood pressure groups. On placebo, the risk of hospitalization for HF increased with lower blood pressure. The beneficial effects of empagliflozin on the primary endpoint and on progression of renal failure were similar irrespective of blood pressure.

Take Home Message

Systolic blood pressure does not modify the effect of empagliflozin on risk. Low blood pressure should not be a barrier to start empagliflozin.



Effect of empagliflozin on blood pressure and outcomes. Effect of empagliflozin on systolic blood pressure (SBP) according to baseline SBP (top), effect of Empa on the primary outcome over the spectrum of baseline SBP (middle), and effect of Empa on the slope of change in estimated glomerular filtration rate (adjusted mean difference, mL/min/1.73 m²/year) (bottom).

Keywords

Empagliflozin • Systolic blood pressure • Heart failure • Preserved ejection fraction • Cardiovascular outcomes • Kidney outcomes

Introduction

Empagliflozin reduced cardiovascular death and heart failure hospitalization in patients with preserved ejection fraction.¹ Hypertension is the most common comorbidity and etiological trigger of heart failure with preserved ejection fraction (HFpEF) as pressure overload produces left ventricular hypertrophy, diastolic dysfunction, abnormal arterial-ventricular coupling, and other complications such as kidney failure.^{2–4} Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce systolic blood pressure (SBP) in patients with diabetes and hypertension,^{5,6} while in heart failure with reduced ejection fraction (HFrEF), only patients with a high baseline SBP had a significant and meaningful

reduction.^{7,8} Registry data show an increase of heart failure outcomes and death for patients with SBP <110 mmHg, which was more pronounced than the risk observed for patients with SBP >140– 150 mmHg without differences between HFrEF and HFpEF.⁹ This U-shaped blood pressure (BP)-risk association might not be related to a causality rather than reflecting reverse causation as low BP selects patients with more advanced heart failure and frailty.^{7,10} In EMPEROR-Preserved (empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction), we studied the effect of empagliflozin on SBP and its effects on heart failure outcomes and estimated glomerular filtration rate (eGFR) decline across baseline SBP levels in heart failure with ejection fraction >40%.

Methods

Study design

The design and results of the EMPEROR-Preserved trial have been published previously.^{1,11} The ethics committees of each of the participating institutions approved the protocol, and all patients gave written informed consent. The registration identifier at ClinicalTrials.gov is NCT03057951.

Studied patients and procedures

Patients with heart failure and ejection fraction >40% were screened, and those fulfilling eligibility criteria were randomized double-blind in a 1:1 fashion to receive placebo or empagliflozin 10 mg daily in addition to their usual therapy for heart failure. Patients with or without diabetes were enrolled. During follow-up, all accompanying treatments could be altered or initiated according to the changes in the clinical status of the patients at the clinical discretion of the investigator. At the screening visit, after the patient had rested quietly in the seated position for 5 min, three attended BP measurements were recorded, and the mean of these three BP values was used to determine eligibility. BP was taken at every subsequent visit using a standard manometer with an appropriate size cuff at the same arm in a sitting position after 5 min of rest.

Patients were assessed at study visits for major outcomes, vital signs, eGFR by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), adverse events and changes in medications or clinical status that reflected changes in the course of heart failure. All randomized individuals were followed for the occurrence of pre-specified outcomes for the entire duration of the trial regardless of whether the study participants had taken the study medication or were adherent with the study procedures according to the intention to treat principle. At the end of double-blind therapy, treatment with study medication was stopped, and patients underwent a follow-up visit including assessment of eGFR 23–45 days later unconfounded by the presence of the study medication.

Outcome measures

The primary endpoint of the composite of adjudicated cardiovascular death or hospitalization for heart failure was analysed as time-to-first event. The first secondary endpoint was the occurrence of all adjudicated hospitalizations for heart failure including first and recurrent events. The second secondary endpoint was the analysis of the slope of the change in eGFR during double-blind treatment.

SBP analyses

Patients were grouped according to their baseline SBP: < 110 mmHg, 110–130 mmHg, and >130 mmHg. Patients were grouped below and above the optimal guideline-recommended SBP targets in cardiovascular high-risk patients (120–130 mmHg). In total, 110–120 mmHg is a grey zone, but outcomes increase below 110 mmHg in observational studies. Systolic blood pressure <110 mmHg was chosen as physicians might be reluctant to use medication at this level. These cut-offs were pre-specified for

EMPEROR-Preserved. The same cut-offs were used previously in EMPEROR-Reduced.⁸ We evaluated the risk of heart failure hospitalization, cardiovascular death (descriptively by event per 100 patient-years), and eGFR decline in these groups in patients treated with placebo, and we compared the effects of empagliflozin vs. placebo on efficacy variables in these SBP categories. Furthermore, in order to understand the influence of postrandomization changes in SBP in mediating the effects of empagliflozin, we studied the treatment effects of empagliflozin using SBP at baseline, Week 4 and time-updated SBP (using the same SBP groups) as a covariate (landmark analyses). We examined the influence of baseline SBP on the occurrence of hypotension, symptomatic hypotension, acute renal failure, and volume depletion in the placebo and empagliflozin groups. Acute renal failure is defined by the standard MedDRA (Medical Dictionary for Regulatory Activities) guery 'Acute renal failure' (narrow scope). Hypotension and volume depletion are based on customized MedDRA gueries, while symptomatic hypotension was based on investigator information (case report form tick box).

Statistical analyses

The effect of empagliflozin compared with placebo on the time-to-first event analyses was examined using Cox proportional hazard regression models with pre-specified covariates of age, sex, geographical region, diabetes status at baseline, left ventricular ejection fraction, and eGFR at baseline. The interaction between (continuous using cubic splines) SBP and treatment group on the occurrence of the pre-specified outcomes was tested using a treatment-by-SBP interaction term. The first secondary outcome of total (first and recurrent) heart failure hospitalizations was evaluated with the use of the joint frailty model that accounted for informative censoring because of cardiovascular death. Changes in SBP and diastolic BP (DBP) were analysed in a mixed model with repeated measures (MMRM). Between-group differences in the slope of change in eGFR were analysed using a random intercept random slope model using on-treatment data. The slope, the joint frailty, and the MMRM models included the same covariates as the Cox model.

All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). All *P*-values reported are two-sided, and P < 0.05 was considered as statistically significant in all cases. No adjustments for multiple testing were made from the exploratory nature of the study.

Results

Patient characteristics

A total of 5988 patients were randomly assigned to receive either empagliflozin (2997 patients, 10 mg once daily) or placebo (2991 patients, Supplementary material online, *Figure S1*). *Table 1* presents the baseline characteristics of patients across SBP categories. Modest interactions of SBP with race and region were observed. Those with lower SBP had a greater severity of heart failure, as evidenced by higher N-terminal pro-B-type natriuretic peptide plasma concentrations, higher heart rate, a higher likelihood of having experienced a heart failure hospitalization in the last 12 months, a higher prevalence of diabetes, lower eGFR and a higher prevalence of albuminuria.

Association of blood pressure with outcomes

The relationship of baseline SBP to the severity of heart failure was further investigated by calculating incidence rates for major endpoints in patients treated with placebo. The incidence rate per 100 patient-years of follow-up for the primary endpoint increased from 8.58 in patients with an SBP >130 mmHg and 8.26 in patients with an SBP of 110– 130 mmHg to 11.59 in patients with an SBP <110 mmHg. (P = 0.12 >

 Table 1
 Baseline characteristics by systolic blood pressure groups

		Systo	lic bloo	d pressure g	group		
	<11	0 mmHg	110-1	130 mmHg	>13	0 mmHg	P-value
Number of patients	455		2415		3118		
Sex [n (%)]							0.2370
Male	244	(53.6%)	1367	(56.6%)	1701	(54.6%)	
Female	211	(46.4%)	1048	(43.4%)	1417	(45.4%)	
Race [n (%)]							0.0002
White	309	(67.9%)	1846	(76.4%)	2387	(76.6%)	
Black/African—American	21	(4.6%)	93	(3.9%)	144	(4.6%)	
Asian	96	(21.1%)	332	(13.7%)	396	(12.7%)	
Other including mixed race	29	(6.4%)	143	(5.9%)	190	(6.1%)	
Missing	0		1	(<0.1%)	1	(<0.1%)	
Region [<i>n</i> (%)]							<0.0001
North America	82	(18.0%)	291	(12.0%)	346	(11.1%)	
Latin America	128	(28.1%)	659	(27.3%)	728	(23.3%)	
Europe	126	(27.7%)	1039	(43.0%)	1524	(48.9%)	
Asia	88	(19.3%)	268	(11.1%)	330	(10.6%)	
Other	31	(6.8%)	158	(6.5%)	190	(6.1%)	
LVEF [% (SD)]	54.1%	(9.0)	53.8	(8.8)	54.8	(8.7)	0.0001
Baseline NT-proBNP (median pg/mL) [(Q1;Q3)]	1104	(557;2092)	1018	(511;1827)	913	(482;1630)	< 0.0001
Baseline BP [mmHg, n (%)]							NA
SBP < 140 and DBP < 90	455	(100.0%)	2346	(97.1%)	1025	(32.9%)	
SBP \geq 140 or DBP \geq 90	0		69	(2.9%)	2093	(67.1%)	
Baseline heart rate (bpm, SD)	71.7	(12.6)	70.7	(12.2)	69.9	(11.5)	0.0021
Baseline weight (kg, SD)	77.79	(18.79)	80.94	(19.05)	83.09	(19.67)	<0.0001
Baseline BMI (kg/m², SD)	28.78	(5.82)	29.39	(5.64)	30.34	(6.00)	<0.0001
Baseline eGFR according to CKD–EPI (mL/min/1.73 m ² , SD)	60.0	(21.6)	60.3	(19.8)	61.0	(19.6)	0.1689
Baseline eGFR according to CKD-EPI [mL/min/1.73 m ² , n (%)]							0.1264
≥60	225	(49.5%)	1180	(48.9%)	1593	(51.1%)	
< 60	230	(50.5%)	1233	(51.1%)	1525	(48.9%)	
Missing	0		2	(0.1%)	0		
Baseline urine albumin-to-creatinine ratio [mg/g, n (%)]							<0.0001
Normal (<30)	300	(65.9%)	1529	(63.3%)	1645	(52.8%)	
Microalbuminuria (30 to ≤300)	136	(29.9%)	713	(29.5%)	1011	(32.4%)	
Macroalbuminuria (>300)	18	(4.0%)	160	(6.6%)	451	(14.5%)	
Missing	1	(0.2%)	13	(0.5%)	11	(0.4%)	
Baseline haemoglobin (g/dL, SD)	13.24	(1.61)	13.25	(1.55)	13.31	(1.58)	0.3921
History of atrial fibrillation or atrial flutter ^a [<i>n</i> (%)]							<0.0001
No	185	(40.7%)	1096	(45.4%)	1563	(50.1%)	
Yes	270	(59.3%)	1314	(54.4%)	1551	(49.7%)	
							Contini

Table 1 Continued

Systolic blood pressure group							
	<110) mmHg	110–1	30 mmHg	>13	0 mmHg	P-value ^c
Missing	0		5	(0.2%)	4	(0.1%)	
Baseline HS Troponin T (ng/L, SD)	25.24	(34.87)	23.46	(23.90)	23.70	(33.28)	0.8831 ^d
History of HHF (in the last 12 months) $[n (\%)]$	124	(27.3%)	569	(23.6%)	676	(21.7%)	0.0173
Cause of HF [n (%)]							0.8633
lschaemic	142	(31.2%)	852	(35.3%)	1123	(36.0%)	
Non-ischaemic	313	(68.8%)	1562	(64.7%)	1995	(64.0%)	
Missing	0		1	(<0.1%)	0		
Diabetes at baseline [n (%)]							<0.0001
Diabetic	194	(42.6%)	1116	(46.2%)	1628	(52.2%)	
Non-diabetic	261	(57.4%)	1299	(53.8%)	1490	(47.8%)	
ACE inhibitors/ARBs/ARNi	347	(76.3%)	1908	(79.0%)	2577	(82.6%)	0.0001
ACE inhibitors/ARBs ^e	320	(70.3%)	1852	(76.7%)	2533	(81.2%)	<0.0001
ARNi	29	(6.4%)	59	(2.4%)	46	(1.5%)	<0.0001
Beta-Blockers	402	(88.4%)	2103	(87.1%)	2662	(85.4%)	0.0774
Diuretics	412	(90.5%)	2112	(87.5%)	2639	(84.6%)	0.0002
Mineralocorticoid receptor antagonists	234	(51.4%)	1028	(42.6%)	982	(31.5%)	<0.0001
Cardiac glycosides	45	(9.9%)	249	(10.3%)	262	(8.4%)	0.0475
Nitrates	49	(10.8%)	295	(12.2%)	402	(12.9%)	0.3944
Calcium channel blockers	85	(18.7%)	621	(25.7%)	1119	(35.9%)	<0.0001
Lipid lowering drugs	293	(64.4%)	1723	(71.3%)	2226	(71.4%)	0.0071
Platelet aggregation inhibitors (excl. heparin)	190	(41.8%)	1106	(45.8%)	1539	(49.4%)	0.0014
Anticoagulants	249	(54.7%)	1241	(51.4%)	1422	(45.6%)	<0.0001
NYHA class at baseline [n (%)]							0.0089
VII	346	(76.0%)	2002	(82.9%)	2539	(81.4%)	
III	107	(23.5%)	404	(16.7%)	572	(18.3%)	
IV	2	(0.4%)	9	(0.4%)	7	(0.2%)	

^aDefined as atrial fibrillation or atrial flutter reported in any ECG before treatment intake or history of atrial fibrillation or atrial flutter reported as medical history. ^bReported either on heart failure history and diagnosis or Health Care Resource Utilization form.

^cANOVA for continuous variables and χ^2 test for categorical variables.

^dbased on log-transformed results.

^eExcluding valsartan when taken with sacubitril, because sacubitril/valsartan is shown as ARNi.


LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; eGFR, estimated glomerular filtration rate; HS, high sensitive; HF, heart failure; HHF, hospitalization for heart failure; NYHA, New York Heart Association; SD, standard deviation.


130 vs. < 110 mmHg, P = 0.08 110–130 vs. < 110 mmHg for comparison of absolute differences in incidence rates).

The incidence rate for cardiovascular death was higher with SBP <110 mmHg [6.61 (4.49–9.13)] compared with 3.04 (2.40–3.75, P < 0.0001 vs. < 110 mmHg) at 110–130 mmHg and 4.01 (3.36–4.71, P = 0.008 vs. < 110 mmHg) at >130 mmHg events per 100 patient-years. For all-cause death, incidence rates per 100 patient-years were 8.53 (6.09–11.37) for <110 mmHg compared with 5.81 (4.91–6.78) for 110–130 mmHg (P = 0.013 vs. 110 mmHg), and 7.07 (6.20–8.00) for >130 mmHg (P = 0.17 vs. < 110 mmHg).

Effect of empagliflozin on blood pressure

The placebo corrected decreases of SBP and DBP were modest (2–4 mmHg drop) and not statistically different across the baseline SBP groups (*Figure 1*). The time course of SBP and DBP in the two treatment groups by baseline SBP categories is shown in Supplementary material online, *Figures S2A* (SBP) and *S2B* (DBP). In patients with <110 mmHg SBP, there was an increase of SBP (see Supplementary material online, *Figure S2A*) and of DBP (see Supplementary material online, *Figure S2A*) and of DBP (see Supplementary material online, *Figure S2B*) from 4 to 172 weeks on placebo and on empagliflozin. A slight increase was observed at 110–130 mmHg, while there was





a decrease at >130 mmHg with placebo and empagliflozin on SBP (A) and DBP (B). We further studied SBP and DBP according to the presence of diabetes (see Supplementary material online, *Table S1*). There were no clinically relevant differences between patients with and without diabetes. Furthermore, the effects of empagliflozin compared with placebo were similar between patients with ejection fraction 40–49% (heart failure with mildly reduced ejection fraction, HFmrEF) and \geq 50% (true HFpEF) (see Supplementary material online, *Table S2*).

Adverse events

The incidence of any adverse events and events leading to discontinuation of the study drug was lower on empagliflozin compared with placebo across all baseline SBP groups. The incidence rates of acute renal failure were overall low and again lower on empagliflozin than on placebo. The incidence rates of volume depletion, hypotension, and symptomatic hypotension were higher at lower SBP and numerically higher on empagliflozin than on placebo. Nevertheless, these events had a low incidence rate (for volume depletion 8.77/100 patient-years placebo vs. 11.77/100 patient-years on empagliflozin, hypotension 7.97/100 patient-years placebo vs. 9.96/100 patient-years, empagliflozin). The rates were lower at higher BP (volume depletion: 4.5/100 patient-years placebo vs. 5.7/100 patient-years on empagliflozin, hypotension 4.04/ 100 patient-years placebo vs. 4.92/100 patient-years on empagliflozin) (*Table 2*).

Effect of empagliflozin on renal function

Figure 2 demonstrates the change in eGFR on empagliflozin or placebo at baseline SBP <110 mmHg, 110–130 mmHg, > 130 mmHg and the slope of eGFR from 4 weeks onwards in the three baseline SBP groups. Empagliflozin reduced the slope of eGFR compared with placebo with significant interaction between the three baseline SBP groups (*P* for interaction <0.0001).

		< 110	< 110 mmHg				110–130 mmHg	mmHg			
	: 20	liflozin		Placebo		ag	iflozin	Placebo	ebo		
Number of patients	22	228	227	17	P-value ^a for treatment	12	:13	12	1202	P-value ^a fo	P-value ^a for treatment
	n (%)	IR/100 pt-yrs	n (%)	IR/100 pt-yrs	comparison	u (%)	IR/100 pt-yrs	n (%)	IR/100 pt-yrs	comp	comparison
Patients with any adverse events	211 (92.5)	239.82	201 (88.5)	194.75	0.16	1047 (86.3)	133.24	1031 (85.8)	142.47	Ö	0.68
Patients with adverse events leading to drug discontinuation	39 (17.1)	9.49	51 (22.5)	12.31	0.23	233 (19.2)	10.29	187 (15.6)	8.20	Ö	0.02
Adverse events of special interest											
Acute renal failure	27 (11.8)	7.11	31 (13.7)	7.93	0.74	146 (12.0)	6.84	155 (12.9)	7.21	Ö	0.50
Volume depletion	43 (18.9)	11.77	34 (15.0)	8.77	0.25	154 (12.7)	7.35	127 (10.6)	5.91	Ö	0.10
Hypotension	37 (16.2)	9.96	31 (13.7)	7.97	0.37	136 (11.2)	6.43	113 (9.4)	5.22	Ö	0.15
Symptomatic hypotension	26 (11.4)	6.81	19 (8.4)	4.78	0.20	85 (7.0)	3.89	67 (5.6)	3.03	Ö	0.15
					> 130 mmHg						
				Empagliflozin	Empagliflozin	Ä	Placebo				
Number of patients				1555		F	1560		P-vali treat comp	P-value for treatment comparison	P-value ^a for trend test
			n (%)	IR/100	lR/100 pt-yrs	n (%)	IR/	IR/100 pt-yrs	-		
Patients with any adverse events			1316 (84.6)	126	128.21 135	1353 (86.7)		147.92	Ö	0.10	0.11
Patients with adverse events leading to drug discontinuation	drug disconti	nuation	299 (19.2)	10	10.20 31:	313 (20.1)		10.83	Ö	0.57	0.03
Adverse events of special interest	¥										
Acute renal failure			190 (12.2)	Ó.	6.86 19	198 (12.7)		7.21	Ö	09.0	0.99
Volume depletion			159 (10.2)	5.	5.70 12	125 (8.0)		4.50	Ö	0.03	0.93
Hypotension			138 (8.9)	4.	4.92	113 (7.2)		4.04	Ö	0.09	0.98
Symptomatic hypotension			86 (5.5)	Э	3.01 70	70 (4.5)		2.46	Ö	0.18	0.87




Figure 2 Change of eGFR over time according to baseline systolic blood pressure. Change in estimated glomerular filtration rate (eGFR) over time in patients on empagliflozin or placebo in patients with a baseline <110 mmHg (A), 110–130 mmHg (B), >130 mmHg (C), and efficacy by baseline systolic blood pressure (SBP) groups for the slope of eGFR (D). eGFR was determined by using the Chronic Kidney Disease Epidemiology Collaboration equation.

Effect of empagliflozin on outcomes

The cumulative incidence function for the primary outcome (cardiovascular death or heart failure hospitalization) according to SBP is shown in Figure 3A. There was a reduction of the primary outcome in all BP groups without a significant difference (P for interaction = 0.69) across groups (Figure 3A). Similar results were observed with time to first adjudicated heart failure hospitalization (Figure 3B, P for interaction = 0.46) and recurrent heart failure hospitalizations (Figure 3C, P for interaction = 0.55). The hazard ratios (left), the event rates (middle), and the treatment effects as a continuous variable across the spectrum of baseline SBP using cubic splines are depicted in Figure 4 on the primary outcome (Figure 4A) and the time to first adjudicated hospitalization for heart failure (Figure 4B). There was a homogeneous treatment effect without interaction with baseline SBP for the primary endpoint (P =0.58) and time to first adjudicated hospitalization for heart failure (P for interaction = 0.66). The event rates for the primary outcome and heart failure hospitalization were higher at baseline SBP <110 mmHg on empagliflozin and placebo, while the treatment effect was similar across the entire spectrum of baseline SBP (Figure 4, right). Empagliflozin's treatment effects were not different on cardiovascular death (P for interaction 0.29) and all-cause death (P for interaction 0.84) across all SBP groups. Next, we evaluated in a landmark analysis the treatment effect of empagliflozin in a standard model and by including baseline SBP, and additionally SBP at 4 weeks and time-updated

mean SBP. With all models, the hazard ratio was 0.80 (P = 0.0014– 0.0016) for the primary endpoint and 0.72–0.73 (P = 0.0001–0.0002) for the first adjudicated hospitalization for heart failure (*Table 3*).

Discussion

In EMPEROR-Preserved, there was a small placebo-corrected SBP decline by empagliflozin compared with placebo with an overall increase of SBP at low baseline SBP and a small drop of SBP at high baseline SBP on placebo and on empagliflozin possibly reflecting regression to the mean. In HFpEF, the outcome rates of the primary outcome were higher at low SBP (<110 mmHg) but the treatment effect of empagliflozin on heart failure outcomes was not significantly related to baseline SBP with a similar risk reduction of heart failure hospitalization and cardiovascular death. Empagliflozin had minor effects on hypotension and volume depletion, while some fewer events were observed for acute renal failure (*Structured Graphical Abstract*).

HFpEF is a heterogeneous condition with hypertension being one of the most prevalent and possible etiological factors promoting the progression of hypertrophy to failure^{12,13} with more patients presenting with a history of hypertension in HFpEF than in HFrEF.¹⁴ A higher prevalence of high BP in HFpEF compared with HFrEF is shown by the finding that 52.0% of the patients had an SBP of >130 mmHg and 7.6% of <110 mmHg in EMPEROR-Preserved (herein), while in




Figure 3 Outcomes across systolic blood pressure. Cumulative incidence function of the effect of empagliflozin and placebo on the primary outcome (A, composite of heart failure hospitalization or cardiovascular death), time to first adjudicated hospitalization for heart failure (B), and recurrent hospitalization for heart failure (C) by baseline systolic blood pressure groups of <110 mmHg (left, a), 110–130 mmHg (middle, b), and >130 mmHg (right, c). *P*-values for interaction are derived from Cox regression model.

EMPEROR-Reduced 28.2% were at >130 mmHg and 24.2% had an SBP of <110 mmHg. 8

Patients with heart failure are often undertreated when SBP is low, although they have a worse prognosis than those with a higher SBP.^{9,15–17} Interestingly, the U- and J-shaped association of SBP and DBP on mortality appears to be similar in HFrEF and HFpEF.⁹ Herein, we show that the primary outcome and cardiovascular death was increased in patients at SBP <110 mmHg compared with >110 mmHg. This finding is similar to previous HFrEF trials^{7,8,18} with treatment effects of SGLT2 inhibitors^{7,8} and sacubitril/valsartan¹⁸ being similar across SBP groups. We extended those findings to HFpEF patients by showing that the effect of empagliflozin is similar across baseline SBP groups in EMPEROR-Preserved.

In EMPEROR-Preserved, 90.6% of patients had a history of hypertension. Although high SBP is a major driver for the development of HFpEF, we still found a significant number with normal or low SBP. Nevertheless, the proportion of patients with low SBP <110 mmHg is lower than in HFrEF.⁸ A reduced myocardial systolic or diastolic function has been speculated to be involved in drops of SBP over time, previously termed 'decapitated hypertension',¹⁹ also observed in PARAGON-HF in HFpEF patients,¹⁸ and associated with increased HF events in HFrEF and HFpEF.^{9,10,18} Similar findings of an increased risk for cardiovascular outcomes at low SBP have also been shown in patients after myocardial infarction or stroke or known coronary artery disease.^{20,21} Nevertheless, in HFpEF as in HFrEF,⁷⁸ SBP appears not to be an effect modifier of the cardio-renal effects of empagliflozin and, thus, might not contribute mechanistically to the treatment effect of empagliflozin.

As the effect of empagliflozin is maintained at SBP <110 mmHg, it is important that the protective effect does not come at a meaningfully increased cost of safety outcomes. There was only a slight increase of incident hypotension or volume depletion, while the incidence of acute renal failure was reduced. These observations are of clinical relevance as physicians are often reluctant to initiate treatment due to the fear of these adverse events at low SBP.²²

Limitations

This study is a *post-hoc* secondary analysis of a randomized trial, and randomization was not stratified by SBP. Unmeasured confounding could have affected the results. The distribution of SBP in HFpEF and EMPEROR-Preserved is different to HFrEF and EMPEROR-Reduced with a rather low number of patients at low baseline SBP. Nevertheless, this is the largest study on HFpEF showing significant treatment effects of the SGLT2 inhibitor empagliflozin with a clear homogeneity of risk reduction across baseline SBP groups.

Conclusion

Empagliflozin reduces the risk of heart failure hospitalization, cardiovascular death, and eGFR decline independently of baseline SBP. The




Figure 4 Treatment effect according to baseline systolic blood pressure. Hazard ratio (left), incident rate per 100 patient-years (middle), and hazard ratio modelled as a continuous variable using cubic splines (right) for empagliflozin compared with placebo according to baseline systolic blood pressure (SBP) for the primary outcome (composite of first heart failure hospitalization or cardiovascular death) (*A*) and time to first adjudicated hospitalization for heart failure (B). CI: confidence interval.

Table 3 Landmark analysis

	Primary endpoint First adjudicated			icated HHF	
	Empagliflozin	Placebo	Empagliflozin	Placebo	
Number of events/number of patients at risk (%)	390/2912 (13.4)	468/2881 (16.2)	242/2912 (8.3)	321/2881 (11.1)	
Standard model					
HR (95% CI)	0.80 (0.7	70, 0.92)	0.72 (0.6	61, 0.85)	
<i>P</i> -value	0.0	014	0.0	001	
Standard model plus baseline SBP (3 cat.)					
HR (95% CI)	0.80 (0.7	70, 0.92)	0.72 (0.6	51, 0.85)	
<i>P</i> -value	0.0	015	0.0	001	
Standard model plus baseline SBP (3 cat.) and	I SBP at week 4 (3 cat.)			
HR (95% CI)	0.80 (0.7	70, 0.92)	0.72 (0.6	51, 0.86)	
<i>P</i> -value	0.0016 0.0002		002		
Standard model plus baseline SBP (3 cat.) and	I SBP at week 4 (3 cat.)+time-updated mea	n		
HR (95% CI)	0.80 (0.3	70, 0.92)	0.73 (0.61, 0.86)		
P-value	0.0	016	0.0002		

Standard model based on a Cox regression model with terms for age, baseline eGFR (CKD–EPI) baseline LVEF, region, diabetes status, sex, and treatment. Only patients with an on-treatment SBP measurement at the Week 4 visit without an event or censoring before the day of the visit 4 SBP measurement are included in the landmark analysis. marginal changes of placebo-corrected SBP on treatment are not responsible for risk reduction with empagliflozin supported by the landmark analysis exploring time-updated SBP on empagliflozin effects. Treatment with empagliflozin is not accompanied by meaningful concerns of symptomatic hypotension or volume depletion but even reduces incident renal failure. A low SBP should not be a barrier for treatment initiation with empagliflozin in heart failure patients with LVEF >40%.

Author contribution

All authors participated in the design of the study, the interpretations of the data, and the writing of the article. The statistical analysis was done by E.S. M.B. drafted the manuscript. All authors were committee members or investigators of the EMPEROR-Preserved trial, or representatives of the Sponsor.

Supplementary data

Supplementary data are available at European Heart Journal online.

Acknowledgement

We are grateful to Armin Schweitzer for technical and editorial help as well as artwork.

Funding

All authors declare no funding for this contribution.

Conflict of interest: M.B. is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TTR 219, project number 322 900 939) and reports personal fees from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Recor, Servier, and Vifor during the conduct of the study. S.D.A reports grants and personal fees from Vifor Int. and Abbott Vascular, and personal fees from Astra-Zeneca, Bayer, Brahms, Boehringer Ingelheim, Cardiac Dimensions, Novartis, Occlutech, Servier, and Vifor Int. Personal fees from Boehringer Ingelheim during the conduct of the study. J.B. reports consulting fees from Boehringer Ingelheim, Cardior, CVRx, Foundry, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, Sequana Medical, V-Wave Ltd., and Vifor. Personal fees from Boehringer Ingelheim during the conduct of the study. J.P.F. reports consulting fees from Boehringer Ingelheim during the conduct of the study. G.F. reports Committee Member contributions in trials. Personal fees from Boehringer Ingelheim during the conduct of the study. F.M. reports grants and personal fees from Medtronic, personal fees from Recor, Boehringer Ingelheim and Berlin Chemie, outside the submitted work; L.L. reports speaker honoraria from Medtronic and ReCor Medical. S.P. reports personal fees from Boehringer Ingelheim during the conduct of the study. I.S. and M.B. are employees of Boehringer Ingelheim. E.S. is employee of mainanalytics, contracted by Boehringer Ingelheim. C.W. reports personal fees from Boehringer Ingelheim during the conduct of the study; personal fees from Akebia, AstraZeneca, Bayer, Eli Lilly, GSK, GILEAD, MSD, Mundipharma, Sanofi-Genzyme, and Vifor Fresenius outside the submitted work; F.Z. has received steering committee or advisory board fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cardior, CVRx, Janssen, Livanova, Merck, Mundipharma, Novartis, Novo Nordisk, and Vifor Fresenius. Personal fees from Boehringer Ingelheim during the conduct of the study. M.P. reports consulting fees from Boehringer Ingelheim, during the conduct of the study; consulting fees from Abbvie, Akcea, Amarin, AstraZeneca, Amgen, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Johnson &

Johnson, Lilly, Novartis, Pfizer, Relypsa, Sanofi, Synthetic Biologics, Theravance, NovoNordisk, outside the submitted work.

Data availability

All authors were involved in the EMPEROR trial, which was funded by Boehringer Ingelheim and Eli Lilly. To ensure independent interpretation of clinical study results and enable authors to fulfil their role and obligations under the ICMJE criteria, Boehringer Ingelheim grants all external authors access to relevant material. In adherence with the Boehringer Ingelheim Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data after publication of the primary manuscript in a peer-reviewed journal, regulatory activities are complete and other criteria are met. Researchers should use the https://vivli.org/link to request access to study data and visit https://www. mystudywindow.com/msw/datasharing for further information.

References

- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461. https://doi.org/10.1056/NEJMoa2107038
- Kasiakogias A, Rosei EA, Camafort M, Ehret G, Faconti L, Ferreira JP, et al. Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. J Hypertens 2021;39:1522–1545. https://doi.org/10.1097/ HJH.00000000002910
- Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. *Hypertension* 2010;**55**:241–248. https:// doi.org/10.1161/HYPERTENSIONAHA.109.138529
- Lam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, et al. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J 2013;34: 676–683. https://doi.org/10.1093/eurheartj/ehs299
- Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. *Diabetes Care* 2015; 38:420–428. https://doi.org/10.2337/dc14-1096
- Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-Hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebocontrolled SACRA Study. *Circulation* 2019;**139**:2089–2097. https://doi.org/10. 1161/CIRCULATIONAHA.118.037076
- Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 2020; 41:3402–3418. https://doi.org/10.1093/eurheartj/ehaa496
- Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure. J Am Coll Cardiol 2021;78:1337–1348. https://doi.org/10.1016/j.jacc.2021.07.049
- Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure. JACC Heart Fail 2017;5:810–819. https://doi.org/10.1016/j.jchf.2017.08.015
- Böhm M, Ewen S. Blood pressure risk associations in heart failure: true effects or inverse causality? JACC Heart Fail 2017;5:820–822. https://doi.org/10.1016/j.jchf.2017.09.010
- Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail 2020;22:2383–2392. https://doi.org/10.1002/ejhf.2064
- Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. *Eur J Heart Fail* 2011;**13**:18–28. https:// doi.org/10.1093/eurjhf/hfq121
- Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 2015; 17:925–935. https:// doi.org/10.1002/ejhf.327
- Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 2017;**70**:2476–2486. https://doi.org/10.1016/j.jacc.2017.08.074
- Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 2017;38:1132–1143. https://doi.org/10.1093/ eurhearti/ehw570
- 16. Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of

Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J 2013;**165**:216–225. https://doi.org/10.1016/j.ahj.2012.11.004

- Komajda M, Böhm M, Borer JS, Ford I, Robertson M, Manolis AJ, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail 2014;16:810–816. https://doi.org/10.1002/ejhf.114
- Selvaraj S, Claggett BL, Böhm M, Anker SD, Vaduganathan M, Zannad F, et al. Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan. J Am Coll Cardiol 2020;**75**:1644–1656. https://doi.org/10.1016/j.jacc.2020. 02.009
- Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail 2017;5:543–551. https://doi.org/10.1016/j.jchf. 2017.04.012
- Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. *Lancet* 2017;**389**:2226–2237. https://doi.org/10.1016/S0140-6736(17)30754-7
- Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016;**388**:2142–2152. https://doi.org/10.1016/S0140-6736(16)31326-5
- Tebbe U, Tschöpe C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 2014;103:665–673. https://doi.org/10. 1007/s00392-014-0678-2